T2 Biosystems, Inc. TTOO announced preliminary results for the second quarter of 2023.
The company is expected to achieve second-quarter total revenue of $2 million. It includes sepsis test panel revenue of $1.3 million, representing an increase of 7% compared to the prior year.
T2 ended the second quarter with a $0.4 million sepsis test backorder.
In the second quarter, T2 secured a multi-year contract with a European distributor for 7 T2Dx Instruments and sepsis test panels for Poland.
T2 implemented a restructuring program in May 2023, including a workforce reduction of nearly 30%.
The company expects to exit the quarter with cash and equivalents worth $16.1 million.
The company now expects full-year 2023 total sepsis and related product revenue of $9.5 million-$10.5 million (down from the prior view of $11.0 million-$13.0 million), representing growth of 13% to 25%, compared to $8.4 million in 2022.
The company plans to announce the complete second quarter 2023 financial results in August.
Price Action: TTOO shares are trading lower by 12% to $0.1318 on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
